Chemotherapy Induced Anemia

Hematology
3
Pipeline Programs
2
Companies
3
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
1
0
2
0
Early DiscoveryClinical DevelopmentMarket

Drug Modality Breakdown

Small Molecule
1100%
+ 2 programs with unclassified modality

Competitive Landscape

2 companies ranked by most advanced pipeline stage

CP
Chugai PharmaJapan - Tokyo
2 programs
2
recombinant human erythropoietinPhase 31 trial
recombinant human erythropoietinPhase 31 trial
Active Trials
NCT00144482Completed122Est. Aug 2005
NCT00144495Completed104Est. May 2005
Astellas
AstellasChina - Shenyang
1 program
1
RoxadustatPhase 2Small Molecule1 trial
Active Trials
NCT04076943Completed92Est. Apr 2021

Trial Timeline

Clinical trial activity over time

2021
2022
2023
2024
2025
2026
Chugai Pharmarecombinant human erythropoietin
Chugai Pharmarecombinant human erythropoietin
AstellasRoxadustat

Clinical Trials (3)

Total enrollment: 318 patients across 3 trials

NCT00144495Chugai Pharmarecombinant human erythropoietin

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Start: Feb 2004Est. completion: May 2005104 patients
Phase 3Completed
NCT00144482Chugai Pharmarecombinant human erythropoietin

A Study of Recombinant Human Erythropoietin in Anemic Cancer Patients Undergoing Chemotherapy

Start: Dec 2003Est. completion: Aug 2005122 patients
Phase 3Completed
NCT04076943AstellasRoxadustat

Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia

Start: Aug 2019Est. completion: Apr 202192 patients
Phase 2Completed

Related Jobs in Hematology

Délégué Médical LLC/Myélome (H/F) - secteurToulouse

Johnson & Johnson
Issy-les-Moulineaux, France
Yesterday

MSL Hematología L - Sur

Johnson & Johnson
Sevilla, Spain
Yesterday

Senior Manager – Strategy & Business Transformation

Johnson & Johnson
Mumbai, India
Yesterday

Sr. Director Marketing

Genetix Biotherapeutics
Somerville, Massachusetts, United States
4d ago
From $270K/yr

Key Account Specialist Hematology

Johnson & Johnson
Beirut, Lebanon
4d ago

Hematology Field Medical Director, non-MD

Pfizer
Remote
4d ago
$177K - $294K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

2 late-stage (Phase 3) programs — potential near-term approvals
2 companies competing in this space

Related Indications

Anemia(92)Myelofibrosis(21)Polycythemia Vera(16)Primary Immune Thrombocytopenia(15)Primary Myelofibrosis(14)Immune Thrombocytopenia(12)Thrombocytopenia(11)Beta-Thalassemia(10)Aplastic Anemia(7)Anemia of Chronic Kidney Disease(7)